Ameritox

Ameritox in the News

  • November 15, 2016
    Ameritox’s Ingenuity Health Announces Research Study from UCLA Center for Health Services and Society

    Results to Focus on the Utility of Urine Drug Monitoring among Behavioral Health Patients

    BALTIMORE, November 15, 2016 — Ingenuity Health, a leading provider of medication monitoring solutions to behavioral health clinicians and a service of AmeritoxSM, today announced it has commissioned a research study by the UCLA Center for Health Services and Society that will help establish the first clinical guidelines for the use of urine drug monitoring among behavioral health patients who have been diagnosed with a serious mental illness. The research for the study has been completed, and the analysis is forthcoming.

    “Using urine drug monitoring is still a very new concept in behavioral health, and this study will give us a solid understanding of how clinicians are utilizing it now, and how it’s helping those same clinicians in treating their patients,” said Ameritox Chief Medical Officer Thomas Smith, MD.

    The UCLA Center for Health Services and Society was selected for their expertise in enhancing the health of communities; access to and quality of care; and qualitative research. All Center publications undergo a rigorous peer review process to verify the accuracy of findings and to gauge their relevance and utility to intended audiences.

    The research findings will be announced by both Ameritox and the UCLA Center for Health Policy Research. Please visit http://hss.semel.ucla.edu for more information about this research institution.

    About Ingenuity Health

    As part of AmeritoxSM, a national leader in medication monitoring solutions, Ingenuity Health utilizes urine drug monitoring to provide highly reliable data and analysis that helps doctors and behavioral health specialists better treat patients diagnosed with serious mental illness.

    Visit the Ingenuity Health website at: www.ingenuityhealth.com
    Follow Ingenuity Health on Twitter: www.twitter.com/ingenuityhealth

    About Ameritox

    Ameritox helped pioneer the prescription drug monitoring necessary to address the national epidemic of prescription drug misuse, abuse and diversion. As a trusted leader in medication monitoring, Ameritox provides medical and business professionals with health care solutions that can help improve patient care and prevent tragedy. Ameritox, headquartered in Baltimore, Md., has laboratory facilities in Greensboro, N.C.

    Visit the Ameritox website at: www.ameritox.com
    Follow Ameritox on Twitter: www.twitter.com/ameritox

    Contact:
    Genevieve Rozansky
    30 Point Strategies
    Genevieve@30point.com
    202-509-0794

    Alexander Young, MD MSHS
    UCLA Center for Health Services and Society
    10920 Wilshire Blvd., Suite 300
    Los Angeles, CA 90024
    310-794-7219



  • November 2, 2016
    Ameritox Study on ADHD Medication Behavior in Adolescents Reveals Which Drug is More Likely to be Misused or Diverted

    Ameritox’s Ingenuity Health Committed to Finding Sub-trends That Will Help Doctors Better Treat and Protect Their Patients

    BALTIMORE, Nov. 2, 2016 /PRNewswire/ — Ingenuity Health, a leading provider of medication monitoring solutions to behavioral health clinicians and a service of AmeritoxSM, today released research showing that patients between the ages of 6 and 25 who are prescribed medication to treat Attention Deficit Hyperactivity Disorder (ADHD) were more likely to test negative for a prescribed amphetamine medication than a prescribed methylphenidate.

    More than 35 percent of patients tested negative for a prescribed amphetamine, compared with just over 26 percent of those who tested negative for prescribed methylphenidate. The research outcomes are based on urine samples collected from patients over a 16-month period.

    “Our research confirmed the ongoing problem of adolescents not taking their prescribed ADHD medication properly with almost 33 percent of the patients testing negative for the prescribed medication,” said Ameritox Chief Medical Officer Thomas Smith, MD. “Interestingly, the study also suggests that the amphetamine drugs are more likely to be misused or diverted than methylphenidate.”

    “One hypothesis in the treating community is that amphetamine- a drug which is highly effective for ADHD – is also more likely to be diverted to the street or shared with friends,” Smith continued. “While our study does not provide proof that this is the case, it does support the hypothesis.”

    “When we begin a study, we seek to either confirm or deny a broad trend within medical research, but we also want to dive down into sub-trends that will help the doctors we serve to better understand their patients, and protect them from dangerous behavior,” said Scott Walton, Ameritox CEO. “This research shows our commitment to isolating the troubling behavior that can lead to poor patient outcomes and potential human tragedy, and to providing clinicians the added knowledge to help prevent it.”

    The Ameritox Medical Affairs team this week presented this research in the form of a medical poster titled “Medication Adherence in Pediatric and Young Adult Patients Prescribed ADHD Stimulant Medications” to the American Academy of Child and Adolescent Psychiatry conference, held in New York. For more information on this conference, please visit: http://www.aacap.org/annualmeeting/2016.

    About Ameritox

    Ameritox helped pioneer the prescription drug monitoring necessary to address the national epidemic of prescription drug misuse, abuse and diversion. As a trusted leader in medication monitoring, Ameritox provides medical and business professionals with health care solutions that can help improve patient care and prevent tragedy. Ameritox, headquartered in Baltimore, Md., has laboratory facilities in Greensboro, N.C.

    Visit the Ameritox website at: www.ameritox.com Follow Ingenuity Health on Twitter: www.twitter.com/ameritox

    About Ingenuity Health

    As part of AmeritoxSM, a national leader in medication monitoring solutions, Ingenuity Health utilizes urine drug monitoring to provide highly reliable data and analysis that helps doctors and behavioral health specialists better treat patients diagnosed with serious mental illness (SMI).

    Visit the Ingenuity Health website at: www.ingenuityhealth.com Follow Ingenuity Health on Twitter: www.twitter.com/ingenuityhealth

    Contact:
    Genevieve Rozansky
    30 Point Strategies
    131692@email4pr.com
    202-509-0794

    SOURCE Ameritox

    Ameritox

    Web Site: http://www.ameritox.com



  • October 26, 2016
    Ameritox: Ingenuity Health Releases Updated Data Revealing Persistent Problem of Medication Non-adherence Among Those with Serious Mental Illness

    Study Also Highlights Dangerous Trend of SMI Patients Misusing and Abusing Benzodiazepines and Non-prescribed Antipsychotic Drugs
     
    BALTIMORE, October 26, 2016 — AmeritoxSM, a national leader in medication monitoring solutions, today announced updated research reaffirming the problem of medication non-adherence among patients prescribed antipsychotic drugs to treat diagnosed Serious Mental Illness (SMI). The study reveals that nearly 25 percent of patient samples tested negative for the prescribed medication.

    “Medication non-adherence among those with SMI can create significant hardship. These patients have increased risk for substance use disorders and negative clinical outcomes such as an increased number of hospital visits and longer stays,” said Ameritox Chief Executive Officer Scott Walton.

    “While our latest research unfortunately confirms a continuing trend, it also reveals a new worry for clinicians – misuse and abuse of benzodiazepines and non-prescribed antipsychotic drugs among those with SMI,” said Ameritox Chief Medical Officer Thomas Smith, MD.

    The study showed that 7.3 percent of samples that tested negative for the prescribed antipsychotic and 5.3 percent of samples that tested positive for the prescribed antipsychotic also contained the presence of a benzodiazepine, such as brand names Xanax®, Valium®, or Ativan®. A non-prescribed antipsychotic medication was found in 6.7 percent of samples.

    “Given the documented harmful effects of drug interactions among benzodiazepines and antipsychotics, misusing or abusing these drugs at the same time can be life-threatening,” Smith said.

    Ameritox conducted its first behavioral health population study in the fall of 2014, with 7,700 patient samples comprising its universe of data. The updated research is based on more than 62,000 samples.

    The Ameritox Medical Affairs team this week presented this research in the form of a medical poster titled “Urine Drug Monitoring in Patients on Prescribed Antipsychotic Medications” to the U.S. Psychiatric and Mental Health Congress, held in San Antonio, Texas. For more information on this conference, please visit: www.psychcongress.com.

    About Ameritox

    Ameritox helped pioneer the prescription drug monitoring necessary to address the national epidemic of prescription drug misuse, abuse and diversion. As a trusted leader in medication monitoring, Ameritox provides medical and business professionals with health care solutions that can help improve patient care and prevent tragedy. Ameritox, headquartered in Baltimore, Md., has laboratory facilities in Greensboro, N.C.

    Contact:
    Genevieve Rozansky
    30 Point Strategies
    genevieve@30point.com
    202-509-0794



  • June 24, 2016
    UNITE holds Shoot Hoops Not Drugs event

    So many life lessons can be learned from the game of basketball,” former University of Kentucky basketball player Jeff Sheppard said. “It’s the least I can do to spend some time with the kids in our communities and deliver a message about basketball but a message of hope as well about staying away from drugs and making the right decisions.”

    Sheppard along with former UK Wildcat Jarrod Polson joined forces with Operation Unite for the 5th Annual Shoot Hoops Not Drugs event. Over 100 children from across the area came to the event to learn basketball fundamentals and an important message about drug abuse.

    “Just the overall message of the camp is just trying to get kids away from the drug scene and how it’s been prevalent in the mountains. Anything to do to prevent that and help those kids and get them on a different path is something I like to do,” Polson said.

    UNITE joined together with Ameritox, a company that “the nation’s leader in pain medication monitoring, offering laboratory services and practice management tools to help clinicians coordinate and optimize the care of chronic pain patients,” according to its website.

    Ameritox’s director of communications, Lon Wagner, said, “We (Ameritox) wanted to sponsor this event. We’re involved in battling the prescription drug epidemic, and so is Operation Unite. Part of our mission, as we say, is to prevent human tragedy.”

    “We want to instill in the kids a couple of things,” Wagner said. “Don’t do drugs that don’t belong to you. Secondly [this camp] is a good, healthy activity. Even if you never end up playing basketball, you’re out here, exercising, getting your heart rate up and doing something positive.”

    Sheppard and Polson taught children of all ages the fundamentals of basketball, ranging from basic ball handling skills to defensive stances. This was the final Shoot Hoops Not Drugs camp that Operation UNITE held.

    Operation UNITE will also be holding a week long leadership camp at the end of July at the University of Cumberlands.

    About Ameritox
    Ameritox helped pioneer the prescription drug monitoring necessary to address the national epidemic of prescription drug misuse, abuse and diversion. As a trusted leader in medication monitoring, Ameritox provides medical and business professionals with health care solutions that can help improve patient care and prevent tragedy. Ameritox, headquartered in Baltimore, Md., has laboratory facilities in Greensboro, N.C.

    Visit the Ameritox website at: www.ameritox.com
    Follow Ameritox on Twitter: www.twitter.com/ameritox

    Contact: Lon Wagner
    Director of Communications, Ameritox
    (336) 387-7742
    lon.wagner@ameritox.com

    Josh Silberberg
    30 Point Strategies
    (202) 304-1546
    joshua@30point.com



  • June 10, 2016
    Ameritox Partners for Third Year with Operation UNITE Youth Basketball Camps Focused on Drug Abuse Prevention

    “Shoot Hoops, Not Drugs” summer basketball camps offer rural Kentucky students the necessary skills to help prevent drug misuse and abuse

    BALTIMORE, MD. – June 10, 2016 — AmeritoxSM, a national leader in medication monitoring solutions, will sponsor for the third consecutive year a series of basketball camps organized by Kentucky-based Operation UNITE. The camps are headed by former University of Kentucky basketball stars who teach basketball skills that also incorporate anti-drug messages aimed at boosting students’ self-worth.

    “By hosting these basketball camps for more than a decade, Operation UNITE has helped instill Eastern Kentucky youth with the self-esteem needed to steer clear of the prescription drug abuse that has devastated their community,” said Scott Walton, Ameritox CEO. “Ameritox is proud to sponsor these camps, because like Operation UNITE, we know that this epidemic can only be stopped by preventing the next generation from succumbing to opioid misuse and abuse.”

    Operation UNITE was created by Kentucky Congressman Hal Rogers in 2003 to bring together government, law enforcement and businesses in fighting Kentucky’s rampant drug problems. The camps were created to foster strong deterrents for drug abuse in school-aged children.

    Ameritox employees will provide support to Operation UNITE staff at the camps.
     
    “We’re grateful to once again have Ameritox’s generous support, but we’re even more grateful that they continue to fight alongside us in the battle to prevent our kids from traveling down the frightening path of drug abuse,” said Nancy Hale, CEO of Operation UNITE.

    The five free 2016 camps will be led by former University of Kentucky Final Four MVP Jeff Sheppard. All-SEC Academic Team member Jarrod Polson will join Sheppard for the last three camps. The dates and locations of the camps are:

    • Tuesday, June 14 – Warfield Middle School, Warfield, Martin County
    • Thursday, June 16 – Owsley County High School, Booneville
    • Monday, June 20 – Morgan County High School, West Liberty
    • Tuesday, June 21 – Rodney C. Woods Gym, Wayne County Schools Campus, Monticello
    • Thursday, June 23 – Knott County Sportsplex, 450 Kenny Champion Loop, Leburn

    About Ameritox
    Ameritox helped pioneer the prescription drug monitoring necessary to address the national epidemic of prescription drug misuse, abuse and diversion. As a trusted leader in medication monitoring, Ameritox provides medical and business professionals with health care solutions that can help improve patient care and prevent tragedy. Ameritox, headquartered in Baltimore, Md., has laboratory facilities in Greensboro, N.C.

    Visit the Ameritox website at: www.ameritox.com
    Follow Ameritox on Twitter: www.twitter.com/ameritox

    About Operation UNITE
    Operation UNITE, which stands for Unlawful Narcotics Investigations, Treatment & Education, seeks to fight the drug epidemic by expanding drug awareness and education programs to keep people from using drugs; coordinating drug treatment and outreach programs for those who are already addicted; and operating regional undercover law enforcement task forces for interdiction and prosecution of those dealing drugs.

    Visit the UNITE website at: www.operationunite.org